Amgen's Options: A Look at What the Big Money Is Thinking
Amgen's Options: A Look at What the Big Money Is Thinking
Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
資金雄厚的投資者們對安進（納斯達克：AMGN）採取了看淡的策略，市場參與者不應忽視這一點。本週財經網站Benzinga對公開期權記錄的追蹤揭示了這一重大舉措。這些投資者的身份仍然是未知的，但在AMGN中出現這樣大規模的舉動通常意味着即將發生重大事件。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
我們從觀察到的Amgen期權掃描儀突出的10項非凡期權活動中獲得了這些信息。這種活動水平是非同尋常的。
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 60% bearish. Among these notable options, 6 are puts, totaling $259,893, and 4 are calls, amounting to $155,093.
這些重量級投資者中普遍情緒不一，40%看好，60%看淡。在這些顯要的期權中，有6個看跌，總計$259,893，4個看漲，總計$155,093。
Expected Price Movements
預期價格波動
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $295.0 to $360.0 for Amgen during the past quarter.
分析這些合同的成交量和持倉量，似乎大戶已經在過去一季度紅範圍內的$295.0至$360.0之間關注Amgen的價格窗口。
Volume & Open Interest Trends
成交量和未平倉量趨勢
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 539.75 with a total volume of 1,599.00.
在流動性和利益方面，今天Amgen期權交易的平均持倉量爲539.75，總成交量爲1,599.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $295.0 to $360.0 over the last 30 days.
在下面的圖表中，我們可以追蹤Amgen重要交易的看漲和看跌期權的成交量和持倉量在$295.0至$360.0的行權價格範圍內在過去30天內的發展。
Amgen Call and Put Volume: 30-Day Overview
安進看漲和看跌成交量：30天概述
Largest Options Trades Observed:
觀察到的最大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 08/09/24 | $8.35 | $7.85 | $8.35 | $327.50 | $70.9K | 62 | 90 |
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $8.8 | $8.2 | $8.8 | $315.00 | $62.4K | 495 | 77 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $50.15 | $49.25 | $50.15 | $300.00 | $50.1K | 1.5K | 0 |
| AMGN | CALL | TRADE | BULLISH | 10/18/24 | $7.65 | $7.55 | $7.65 | $360.00 | $48.1K | 397 | 343 |
| AMGN | PUT | TRADE | BULLISH | 01/17/25 | $19.35 | $18.55 | $18.55 | $310.00 | $33.3K | 1.0K | 20 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看跌 | SWEEP | 看淡 | 08/09/24 | $8.35 | $7.85 | $8.35 | $327.50 | $70.9千 | 62 | 90 |
| AMGN | 看跌 | SWEEP | 看淡 | 10/18/24 | $ 8.8 | $8.2 | $ 8.8 | $315.00 | $62.4千美元 | 495 | 77 |
| AMGN | 看漲 | 交易 | 看好 | 01/17/25 | $50.15 | $49.25 | $50.15 | $ 300.00 | $50.1K | 1.5K | 0 |
| AMGN | 看漲 | 交易 | 看好 | 10/18/24 | $7.65 | $7.55 | $7.65 | $360.00 | $48.1K | 397 | 343 |
| AMGN | 看跌 | 交易 | 看好 | 01/17/25 | $19.35 | $18.55 | $18.55 | $ 310.00 | $33.3K | 1.0K | 20 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
在我們分析與安進相關的期權活動之後，我們將轉向更仔細地研究公司自身的表現。
Current Position of Amgen
安進的當前位置
- With a volume of 1,143,672, the price of AMGN is down -0.98% at $332.25.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 4 days.
- 伴隨着1,143,672的成交量，AMGN的價格下跌-0.98%，爲$332.25。
- RSI指標暗示該股票可能要超買了。
- 下一季度收益預計將在4天內發佈。
What Analysts Are Saying About Amgen
分析師對安進的評論
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $303.0.
在過去30天中，總共有1名專業分析師發表了他們對這隻股票的看法，設定了平均目標價爲$303.0。
- An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $303.
- 摩根士丹利的一位分析師決定維持對安進的中性評級，目標股價目前爲303美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期權交易具有更高的風險和潛在回報。精明的交易者通過不斷學習、調整策略、監控多個因子和密切關注市場走勢來管理這些風險。通過Benzinga Pro的實時提醒了解最新的安進期權交易。